- Home
- ACAD vs ITGR Comparison
ACAD vs ITGR Comparison
Compare ACAD & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- ITGR
- Stock Information
- Founded
- ACAD 1993
- ITGR 1970
- Country
- ACAD United States
- ITGR United States
- Employees
- ACAD N/A
- ITGR N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- ITGR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ACAD Health Care
- ITGR Health Care
- Exchange
- ACAD Nasdaq
- ITGR Nasdaq
- Market Cap
- ACAD 3.5B
- ITGR 3.6B
- IPO Year
- ACAD 2004
- ITGR 2000
- Fundamental
- Price
- ACAD $21.09
- ITGR $107.43
- Analyst Decision
- ACAD Buy
- ITGR Strong Buy
- Analyst Count
- ACAD 20
- ITGR 8
- Target Price
- ACAD $29.25
- ITGR $139.38
- AVG Volume (30 Days)
- ACAD 2.5M
- ITGR 398.5K
- Earning Date
- ACAD 11-05-2025
- ITGR 10-23-2025
- Dividend Yield
- ACAD N/A
- ITGR N/A
- EPS Growth
- ACAD 615.00
- ITGR N/A
- EPS
- ACAD 1.33
- ITGR 2.31
- Revenue
- ACAD $1,018,885,000.00
- ITGR $1,794,800,000.00
- Revenue This Year
- ACAD $14.01
- ITGR $10.92
- Revenue Next Year
- ACAD $11.81
- ITGR $7.35
- P/E Ratio
- ACAD $15.76
- ITGR $44.81
- Revenue Growth
- ACAD 14.41
- ITGR 9.64
- 52 Week Low
- ACAD $13.40
- ITGR $99.54
- 52 Week High
- ACAD $26.65
- ITGR $146.36
- Technical
- Relative Strength Index (RSI)
- ACAD 43.19
- ITGR 59.90
- Support Level
- ACAD $20.33
- ITGR $102.20
- Resistance Level
- ACAD $22.10
- ITGR $105.30
- Average True Range (ATR)
- ACAD 0.78
- ITGR 2.63
- MACD
- ACAD 0.08
- ITGR 0.47
- Stochastic Oscillator
- ACAD 58.09
- ITGR 99.62
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.